Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain.
In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies.
Most recently, Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
On Wednesday, Eli Lilly And Co (NYSE: LLY) completed the acquisition of POINT Biopharma Global Inc (NASDAQ: PNT) for $12.50 per share in cash, an aggregate of approximately $1.4 billion.
These transactions indicate that Fusion stands as the final feasible option, poised to serve as a cornerstone for a major pharmaceutical company aiming to establish a significant presence in targeted radiopharmaceuticals.
The analyst writes that Fusion stands out as the sole TRT player engaged in a productive therapeutic partnership with AstraZeneca Plc (NASDAQ: AZN), which was announced in 2020.
The collaboration concentrates on advancing AstraZeneca and Fusion candidates as targeted radiotherapies, with a profit-sharing agreement between the partnering entities.
The partnership could potentially position AstraZeneca favorably for future acquisition opportunities.
Raymond James upgraded Fusion Pharmaceuticals from Outperform to a Strong Buy, with a price target of $15, up from $12.
Price Action: FUSN shares are up 11.4% at $8.88 on the last check Wednesday.
Latest Ratings for FUSN
Date | Firm | Action | From | To |
|---|---|---|---|---|
Aug 2021 | B. Riley Securities | Initiates Coverage On | Buy | |
Aug 2021 | Morgan Stanley | Maintains | Overweight | |
May 2021 | Morgan Stanley | Maintains | Overweight |
View More Analyst Ratings for FUSN
View the Latest Analyst Ratings
"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga?
This article Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned originally appeared on Benzinga.com
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
